These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22957772)

  • 21. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Sallee FR; Lyne A; Wigal T; McGough JJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; McBurnett K; White C; Youcha S
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling and simulation of the exposure-response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD.
    Knebel W; Rogers J; Polhamus D; Ermer J; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):45-65. PubMed ID: 25373474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M; McBurnett K; Cutler AJ; Hervás A; Bliss C; Gao J; Dirks B; Newcorn JH
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada.
    Lachaine J; Ben Amor L; Pringsheim T; Burns J; van Stralen J
    J Child Adolesc Psychopharmacol; 2019 Dec; 29(10):730-739. PubMed ID: 31433205
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Connor DF; Rubin J
    Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
    Newcorn JH; Harpin V; Huss M; Lyne A; Sikirica V; Johnson M; Ramos-Quiroga JA; van Stralen J; Dutray B; Sreckovic S; Bloomfield R; Robertson B
    J Child Psychol Psychiatry; 2016 Jun; 57(6):717-28. PubMed ID: 26871297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ; Perry CM
    Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder.
    Newcorn JH; Huss M; Connor DF; Hervás A; Werner-Kiechle T; Robertson B
    J Dev Behav Pediatr; 2020 Sep; 41(7):565-570. PubMed ID: 32482970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Signorovitch J; Erder MH; Xie J; Sikirica V; Lu M; Hodgkins PS; Wu EQ
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():130-7. PubMed ID: 22552988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.
    Huss M; Chen W; Ludolph AG
    Clin Drug Investig; 2016 Jan; 36(1):1-25. PubMed ID: 26585576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.
    Connor DF; Grasso DJ; Slivinsky MD; Pearson GS; Banga A
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):244-51. PubMed ID: 23683139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.